ATC code L04

ATC codes
L Antineoplastic and immunomodulating agents
L01 Antineoplastic agents
L02 Endocrine therapy
L03 Immunostimulants
L04 Immunosuppressants
A B C D G H QI J L M N P R S V (Hover over links to see titles)

ATC code L04 Immunosuppressants is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.<ref>

ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis(link). {{{website}}}. National Institutes of Health.

</ref><ref>

ATC-Klassifikation mit definierten Tagesdosen DDD(link). {{{website}}}. German Institute for Medical Documentation and Information.

</ref> Subgroup L04 is part of the anatomical group L Antineoplastic and immunomodulating agents.<ref>

ATC/DDD Index 2022

code L04(link).

{{{website}}}. WHO Collaborating Centre for Drug Statistics Methodology.

</ref>

Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QL04.<ref>

ATCvet Index 2022

code QL04(link).

{{{website}}}. WHO Collaborating Centre for Drug Statistics Methodology.

</ref>

National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.

L04A Immunosuppressants

L04AA Selective immunosuppressants

L04AA02 Muromonab-CD3

L04AA03 Antilymphocyte immunoglobulin (horse)

L04AA04 Antithymocyte immunoglobulin (rabbit)

L04AA06 Mycophenolic acid

L04AA10 Sirolimus

L04AA13 Leflunomide

L04AA15 Alefacept

L04AA18 Everolimus

L04AA19 Gusperimus

L04AA21 Efalizumab

L04AA22 Abetimus

L04AA23 Natalizumab

L04AA24 Abatacept

L04AA25 Eculizumab

L04AA26 Belimumab

L04AA27 Fingolimod

L04AA28 Belatacept

L04AA29 Tofacitinib

L04AA31 Teriflunomide

L04AA32 Apremilast

L04AA33 Vedolizumab

L04AA34 Alemtuzumab

L04AA35 Begelomab

L04AA36 Ocrelizumab

L04AA37 Baricitinib

L04AA38 Ozanimod

L04AA39 Emapalumab

L04AA40 Cladribine

L04AB Tumor necrosis factor alpha (TNF-α) inhibitors

L04AB01 Etanercept

L04AB02 Infliximab

L04AB03 Afelimomab

L04AB04 Adalimumab

L04AB05 Certolizumab pegol

L04AB06 Golimumab

L04AC Interleukin inhibitors

L04AC01 Daclizumab

L04AC02 Basiliximab

L04AC03 Anakinra

L04AC04 Rilonacept

L04AC05 Ustekinumab

L04AC07 Tocilizumab

L04AC08 Canakinumab

L04AC09 Briakinumab

L04AC10 Secukinumab

L04AC11 Siltuximab

L04AC12 Brodalumab

L04AC13 Ixekizumab

L04AC14 Sarilumab

L04AC15 Sirukumab

L04AC16 Guselkumab

L04AC17 Tildrakizumab

L04AD Calcineurin inhibitors

L04AD01 Ciclosporin

L04AD02 Tacrolimus

L04AD03 Voclosporin

L04AX Other immunosuppressants

L04AX01 Azathioprine

L04AX02 Thalidomide

L04AX03 Methotrexate

L04AX04 Lenalidomide

L04AX05 Pirfenidone

L04AX06 Pomalidomide